Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 2

Status

Recruiting 17Active not recruiting 8Not yet recruiting 6Completed 5Unknown 3Terminated 3Withdrawn 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 3Lymphoma 3Lymphoma, B-Cell 2Recurrence 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 187Cyclophosphamide 174Etoposide 94Peripheral Blood Stem Cell Transplantation 90Vincristine 89Prednisone 80Doxorubicin 79Filgrastim 75fludarabine phosphate 60Radiotherapy 56Mycophenolic Acid 41Melphalan 41Cytarabine 41Busulfan 40Cyclosporine 39Methotrexate 37Whole-Body Irradiation 36Tacrolimus 35Carmustine 34Ifosfamide 28Lenalidomide 27Granulocyte Colony-Stimulating Factor 27Antilymphocyte Serum 27Gemcitabine 25Carboplatin 25Methylprednisolone 24ibritumomab tiuxetan 23Bortezomib 22Dexamethasone 21ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Lymphoma, Large B-Cell, Diffuse × polatuzumab vedotin × Clear all
NCT03274492 2026-05-08

POLARIX

Hoffmann-La Roche

Phase 3 Completed
1,000 enrolled 1 FDA
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04182204 2025-12-22

POLARGO

Hoffmann-La Roche

Phase 3 Completed
270 enrolled 36 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03677154 2025-08-21

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Hoffmann-La Roche

Phase 1/2 Completed
188 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02600897 2023-12-26

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Hoffmann-La Roche

Phase 1/2 Completed
114 enrolled 34 charts
Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01691898 2020-02-21

ROMULUS

Genentech, Inc.

Phase 1/2 Completed
231 enrolled 64 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡